Advertisement

Topics

Kite files CAR-T therapy in EU, ahead of Novartis rival

07:58 EDT 1 Aug 2017 | pharmaphorum

Kite Pharma has filed its CAR-T cancer therapy in Europe in certain types of non-Hodgkin lymphoma, hoping to get to market ahead of close rival Novartis with some impressive efficacy data. In the US, Novartis is just ahead with its rival chimeric ...

Original Article: Kite files CAR-T therapy in EU, ahead of Novartis rival

NEXT ARTICLE

More From BioPortfolio on "Kite files CAR-T therapy in EU, ahead of Novartis rival"

Quick Search
Advertisement
 

Relevant Topics

Cancer Disease
Cancer is not just one disease but many diseases. There are more than 100 different types of cancer. Most cancers are named for the organ or type of cell in which they start - for example, cancer that begins in the colon is called colon cancer; cancer th...

Hodgkin lymphoma
Hodgkin Lymphoma is a  disorder caused by malignant proliferation of lymphocytes, which contain characteristic mirror-image nuclei (Reed-Sternburg cells). The resulting lymphadenopathy can be limited to a single lymph node region (Stage 1) or spread...

The Top 100 Pharmaceutical Companies
Top 10 biotech and pharmaceutical companies worldwide based on market value in 2015 2015 ranking of the global top 10 biotech and pharmaceutical companies based on revenue (in billion U.S. dollars) Johnson & Johnson, U.S. 74...